J and J vaccine cures monkey in a single shot
Representational Pic
A leading candidate of Covid-19 vaccine developed by global healthcare company Johnson & Johnson raised neutralising antibodies and robustly protected monkeys against SARS-CoV-2, the virus that causes Covid-19
New York: A leading candidate of Covid-19 vaccine developed by global healthcare company Johnson & Johnson raised neutralising antibodies and robustly protected monkeys against SARS-CoV-2, the virus that causes Covid-19.
The vaccine uses a common cold virus, called adenovirus serotype 26 (Ad26), to deliver the SARS-CoV-2 spike protein into host cells, where it stimulates the body to raise immune responses against the coronavirus.
Barouch has been working on the development of a Covid-19 vaccine since January when Chinese scientists released the SARS-CoV-2 genome. The research team developed a series of vaccine candidates designed to express different variants of the SARS-CoV-2 spike protein, which is the major target for neutralizing antibodies.
They conducted a study in 52 NHPs, immunizing 32 adult rhesus macaques (monkeys) with a single dose of one of seven different versions of the Ad26-based vaccine, and giving 20 animals sham vaccines as placebo controls. All 20 animals that received the sham vaccine became infected and showed high levels of virus in their lungs and nasal swabs.
Of the six animals that received the optimal vaccine candidate, Ad26.COV2.S, none showed the virus in their lungs, and only one animal showed low levels of virus in nasal swabs.
